Hologic Inc（HOLX）のニュースとイベントHOLXHologic Inc

Hologic Signs Agreement to Acquire Reveal Genomics

Hologic announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Completion of the acquisition is subject to Spanish regulatory approval and other customary closing conditions. "Reveal Genomics' portfolio is a strong strategic complement to our existing oncology offering within Diagnostic Solutions and would allow us to support even more women diagnosed with breast cancer. This acquisition demonstrates our commitment to innovation and meaningfully expands our ability to inform breast cancer treatment decisions, directly advancing our purpose to enable healthier lives everywhere, every day," said Vitor Rocha, CEO, Diagnostic Solutions at Hologic.

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

Hologic announced a victory in the Unified Patent Court in Germany, which it says ruled that Siemens infringed upon a Hologic mammography technology patent in Siemens' latest mammography system. "The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries," Hologic said in a statement. Hologic will receive retroactive and future damages and costs to be determined by the court. Siemens must also refund customers of the infringing systems for the purchase price paid and reimburse them for logistics and related costs as part of the recall, the company added.